Hepatocellular carcinoma (HCC) ranks as a leading cause of cancer-related deaths. A recent article identified UFMylation as a suppressor of HCC metastasis. Xu et al. show that UFMylation is lost in HCC and this destabilizes the nuclear-membrane protein emerin, which promotes its degradation, thereby enabling the nuclear accumulation of β-catenin. Under physiological conditions, emerin prevents the nuclear localization of β-catenin. However, via nuclear β-catenin accumulation, loss of UFMylation leads to activation of transcriptional signatures associated with a pattern consistent with hybrid epithelial–mesenchymal transition (EMT), characterized by the expression of both epithelial and mesenchymal markers and enhanced cellular plasticity. The authors show that nuclear β-catenin drives increased migration, invasion, proliferation, and metastatic dissemination of HCC cells. Using mouse models, Xu et al. show that these changes all depend on emerin. The authors further demonstrate that nuclear β-catenin contributes to immune evasion by upregulating the expression of poliovirus receptor, thereby reducing the susceptibility of HCC cells to natural-killer cell surveillance. Conversely, restoration of emerin expression in UFMylation-deficient cells reduced nuclear β-catenin availability and reversed both EMT markers and immune-evasive transcriptional signatures and phenotypes. These findings establish the functional role of UFMylation-dependent stabilization of emerin in the regulation of β-catenin in HCC.
- Open Access
- Perspective
UFMylation-Dependent Stabilization of Emerin Suppresses Hepatocellular Carcinoma via β-Catenin
Author Information
Received: 26 Jun 2026 | Revised: 28 Aug 2026 | Accepted: 03 Sep 2026 | Published: 09 Sep 2026
Abstract
Keywords
UFMylation | hepatocellular carcinoma | emerin | β-catenin | epithelial-mesenchymal transition | poliovirus receptor
References
- 1.
Komatsu, M.; Chiba, T.; Tatsumi, K.; et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 2004, 23, 1977–1986. https://doi.org/10.1038/sj.emboj.7600205.
- 2.
Tatsumi, K.; Sou, Y.S.; Tada, N.; et al. A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. 2010, 285, 5417–5427. https://doi.org/10.1074/jbc.m109.036814.
- 3.
Kang, S.H.; Kim, G.R.; Seong, M.; et al. Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J. Biol. Chem. 2007, 282, 5256–5262. https://doi.org/10.1074/jbc.m610590200.
- 4.
Komatsu, M.; Noda, N.N.; Inada, T. The mechanistic basis and cellular functions of UFMylation. Nat. Rev. Mol. Cell Biol. 2026, 27, 419–432. https://doi.org/10.1038/s41580-025-00944-y.
- 5.
Komatsu, M.; Inada, T.; Noda, N.N. The UFM1 system: Working principles, cellular functions, and pathophysiology. Mol. Cell 2024, 84, 156–169. https://doi.org/10.1016/j.molcel.2023.11.034.
- 6.
Wang, R.N.; Li, L.; Zhou, J.; et al. Multifaceted roles of UFMylation in health and disease. Acta Pharmacol. Sin. 2025, 46, 805–815. https://doi.org/10.1038/s41401-024-01456-9.
- 7.
Zhou, J.; Ma, X.; He, X.; et al. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target. Proc. Natl. Acad. Sci. USA 2023, 120, e2215732120. https://doi.org/10.1073/pnas.2215732120. Corrected in Proc. Natl. Acad. Sci. USA 2023, 120, e2306087120.
- 8.
Liu, J.; Guan, D.; Dong, M.; et al. UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nat. Cell Biol. 2020, 22, 1056–1063. https://doi.org/10.1038/s41556-020-0559-z.
- 9.
Zhou, J.; Ma, X.; Xu, L.; et al. Genomic profiling of the UFMylation family genes identifies UFSP2 as a potential tumour suppressor in colon cancer. Clin. Transl. Med. 2021, 11, e642. https://doi.org/10.1002/ctm2.642.
- 10.
Fang, B.; Li, Z.; Qiu, Y.; et al. Inhibition of UBA5 Expression and Induction of Autophagy in Breast Cancer Cells by Usenamine A. Biomolecules 2021, 11, 1348. https://doi.org/10.3390/biom11091348.
- 11.
Chen, F.; Sheng, L.; Zhou, T.; et al. Loss of Ufl1/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling. J. Exp. Clin. Cancer Res. 2023, 42, 110. https://doi.org/10.1186/s13046-023-02681-6.
- 12.
Xu, M.; Gao, X.; Zhao, J.; et al. UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting beta-catenin-Driven Hybrid EMT and NK Cell Evasion. Cancer Res. 2026, 86, 3213–3232. https://doi.org/10.1158/0008-5472.can-25-4755.
- 13.
Denisov, E.V.; Perelmuter, V.M. A fixed partial epithelial-mesenchymal transition (EMT) triggers carcinogenesis, whereas asymmetrical division of hybrid EMT cells drives cancer progression. Hepatology 2018, 68, 807–810. https://doi.org/10.1002/hep.29784.
- 14.
Markiewicz, E.; Tilgner, K.; Barker, N.; et al. The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus. EMBO J. 2006, 25, 3275–3285. https://doi.org/10.1038/sj.emboj.7601230.
- 15.
Wu, K.Y.; Xie, H.; Zhang, Z.L.; et al. Emerin knockdown induces the migration and invasion of hepatocellular carcinoma cells by up-regulating the cytoplasmic p21. Neoplasma 2022, 69, 59–70. https://doi.org/10.4149/neo_2021_210728n1059.
- 16.
Liu, L.; You, X.; Han, S.; et al. CD155/TIGIT, a novel immune checkpoint in human cancers (Review). Oncol. Rep. 2021, 45, 835–845. https://doi.org/10.3892/or.2021.7943.
- 17.
Sun, Y.; Li, T.; Ding, L.; et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology 2025, 81, 791–807. https://doi.org/10.1097/hep.0000000000000934.
- 18.
Boussiotis, V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N. Engl. J. Med. 2016, 375, 1767–1778. https://doi.org/10.1056/nejmra1514296.
- 19.
Buchwalter, A.; Schulte, R.; Tsai, H.; et al. Selective clearance of the inner nuclear membrane protein emerin by vesicular transport during ER stress. eLife 2019, 8, e49796. https://doi.org/10.7554/elife.49796.
- 20.
Mao, Z.; Ma, X.; Jing, Y.; et al. Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress. Cell Death Dis. 2023, 14, 584. https://doi.org/10.1038/s41419-023-06095-2.
- 21.
Rumgay, H.; Arnold, M.; Ferlay, J.; et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 2022, 77, 1598–1606. https://doi.org/10.1016/j.jhep.2022.08.021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com